ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
23/02/2024
STATUS:
Authorized
ACTIVE PRINCIPLE:
Believable
INDICATION:
plaque psoriasis
Psoriasic arthritis
Crohn's disease
Ulcerative colitis
DATE:
11/01/2024
STATUS:
Authorized
ACTIVE PRINCIPLE:
natalizumab
INDICATION:
Multiple sclerosis
DATE:
29/09/2023
STATUS:
Authorized
ACTIVE PRINCIPLE:
Tocilizumab
INDICATION:
Rheumatoid Arthritis
Cytokine release syndrome
Juvenile rheumatoid arthritis
COVID-19 virus infection
Giant cell arteritis
DATE:
21/09/2023
STATUS:
Authorized
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
20/06/2023
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
27/04/2023
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
27/04/2023
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
22/11/2022
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
05/10/2022
STATUS:
Authorized
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
29/09/2022
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
06/06/2022
STATUS:
Authorized
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
17/05/2022
STATUS:
Authorized
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Psoriasic arthritis
Juvenile rheumatoid arthritis
Rheumatoid Arthritis
Ulcerative colitis
Crohn's disease
Hidradenitis suppurativa
Psoriasis
Ankylosing spondylitis
Uveitis
DATE:
28/12/2021
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
28/05/2021
STATUS:
Authorized
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
08/04/2021
STATUS:
Authorized
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Psoriasis
Psoriasic arthritis
Ankylosing spondylitis
Uveitis
Ulcerative colitis
Crohn's disease
Hidradenitis suppurativa
DATE:
31/03/2021
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
08/01/2021
STATUS:
Authorized
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Non-small cell lung carcinoma
Renal cell carcinoma
DATE:
29/12/2020
STATUS:
Authorized
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
20/10/2020
STATUS:
Authorized
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer
DATE:
07/09/2020
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
03/08/2020
STATUS:
Authorized
MORE INFORMATION
ACTIVE PRINCIPLE:
Rituximab
INDICATION:
B-cell chronic lymphocytic leukemia
Rheumatoid Arthritis
microscopic polyangiitis
Pemphigus
DATE:
26/04/2020
STATUS:
Authorized
ACTIVE PRINCIPLE:
pegfilgrastim
INDICATION:
neutropenia
DATE:
25/10/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Cervical cancer
DATE:
30/09/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
Bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Ovarian, fallopian tube and peritoneal cancer
Cervical cancer
DATE:
27/09/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
08/08/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Psoriasic arthritis
Ulcerative colitis
Crohn's disease
Psoriasis
Ankylosing spondylitis
Hidradenitis suppurativa
Uveitis
DATE:
08/07/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
23/05/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
28/02/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
Insulin glargine
INDICATION:
Diabetes mellitus type 2
DATE:
25/02/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
08/02/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
31/01/2019
STATUS:
Authorized
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
12/12/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
breast and stomach cancer
DATE:
30/11/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
15/11/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
31/10/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
27/09/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
papulosquamous diseases
Juvenile rheumatoid arthritis
DATE:
16/08/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
01/08/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Ankylosing spondylitis
Rheumatoid arthritis
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
16/07/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
28/05/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
Arthritis
Uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
25/05/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile idiopathic arthritis
axial spondylitis
Psoriasic arthritis
Psoriasis
Pediatric plaque psoriasis
Hidradenitis suppurativa
Crohn's disease
Pediatric Crohn's disease
Ulcerative colitis
Uveitis
pediatric uveitis
DATE:
13/04/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
13/04/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
16/03/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
16/03/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
27/02/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Enoxaparin Sodium
INDICATION:
venous thrombosis
DATE:
20/02/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Wegener's granulomatosis
microscopic polyangiitis
Rheumatoid Arthritis
Non-Hodgkin lymphoma
B-cell chronic lymphocytic leukemia
DATE:
31/07/2017
STATUS:
Authorized
ACTIVE PRINCIPLE:
etanercept
INDICATION:
Psoriasic arthritis
Psoriasis
Juvenile rheumatoid arthritis
Rheumatoid Arthritis
Ankylosing spondylitis
DATE:
26/07/2017
STATUS:
Authorized
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Wegener's granulomatosis
microscopic polyangiitis
Rheumatoid Arthritis
Non-Hodgkin lymphoma
DATE:
26/07/2017
STATUS:
Authorized
ACTIVE PRINCIPLE:
Rituximab
INDICATION:
Rheumatoid Arthritis
Non-Hodgkins lymphoma
Chronic lymphocytic leukemia
Granulomatosis with polyangiitis
microscopic polyangiitis
DATE:
07/04/2017
STATUS:
Authorized
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Psoriasic arthritis
Rheumatoid Arthritis
Psoriasis
Ulcerative colitis
Crohn's disease
Ankylosing spondylitis
DATE:
07/07/2016
STATUS:
Authorized
ACTIVE PRINCIPLE:
Insulin glargine
INDICATION:
Diabetes Mellitus
DATE:
23/06/2016
STATUS:
Authorized
ACTIVE PRINCIPLE:
etanercept
INDICATION:
Psoriasic arthritis
Rheumatoid Arthritis
plaque psoriasis
Ankylosing spondylitis
DATE:
25/02/2016
STATUS:
Authorized
ACTIVE PRINCIPLE:
follitropin alfa
INDICATION:
Anovulation
DATE:
16/02/2015
STATUS:
Authorized
ACTIVE PRINCIPLE:
filgrastim
INDICATION:
neutropenia
DATE:
10/10/2014
STATUS:
Authorized
ACTIVE PRINCIPLE:
follitropin alfa
INDICATION:
Anovulation
DATE:
23/06/2014
STATUS:
Authorized
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Rheumatoid Arthritis
Crohn's disease
Ulcerative colitis
Ankylosing spondylitis
Psoriasic arthritis
Psoriasis
DATE:
23/06/2014
STATUS:
Authorized
ACTIVE PRINCIPLE:
Infliximab
INDICATION:
Rheumatoid Arthritis
Crohn's disease
Ulcerative colitis
Ankylosing spondylitis
Psoriasic arthritis
Psoriasis
DATE:
25/03/2014
STATUS:
Authorized
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
19/10/2010
STATUS:
Authorized
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
07/12/2009
STATUS:
Authorized
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
31/03/2009
STATUS:
Authorized
ACTIVE PRINCIPLE:
Filgastrim
INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation
DATE:
25/09/2008
STATUS:
Authorized
ACTIVE PRINCIPLE:
Epoetin Zeta
INDICATION:
Anemia secondary to oncological processes
end-stage renal failure
DATE:
27/02/2008
STATUS:
Authorized
ACTIVE PRINCIPLE:
epoetin alfa
INDICATION:
Anemia secondary to oncological processes
end-stage renal failure
DATE:
18/02/2008
STATUS:
Authorized
ACTIVE PRINCIPLE:
Somatotropin
INDICATION:
Dwarfism
Prader-Willi syndrome
Turner syndrome
DATE:
06/07/2006
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.